862207-71-4

Basic information

• Product Name: Solifenacin Related CoMpound 4 Succinate
• Synonyms: Solifenacin Related CoMpound 4 Succinate;Solifenacin EP Impurity H Succinate;(S)-(S)-quinuclidin-3-yl 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate;Solifenacin EP Impurity H
• CAS NO: 862207-71-4
• Molecular Formula: C₄H₆O₄*C₂₃H₂₆N₂O₂
• Molecular Weight: 480.55278
• Mol File: 862207-71-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Solifenacin Related CoMpound 4 Succinate(CAS DataBase Reference)
• NIST Chemistry Reference: Solifenacin Related CoMpound 4 Succinate(862207-71-4)
• EPA Substance Registry System: Solifenacin Related CoMpound 4 Succinate(862207-71-4)

Safety Data

• Hazardous Substances Data: 862207-71-4(Hazardous Substances Data)

Usage

Description

Solifenacin Related Compound 4 Succinate is a muscarinic M3 receptor antagonist, which is a derivative of the active pharmaceutical ingredient Solifenacin Succinate. It is a chemical compound that has the potential to be used in the development of medications for various therapeutic applications.

Uses

Used in Pharmaceutical Industry:
Solifenacin Related Compound 4 Succinate is used as a muscarinic M3 receptor antagonist for the treatment of urinary incontinence. It works by blocking the action of acetylcholine on the M3 receptors in the bladder, which helps to reduce the frequency and urgency of urination, thereby providing relief to patients suffering from this condition.

Upstream product

• 110-15-6 succinic acid 
• 242478-37-1 solifenacin 
• 732228-02-3 (1S)-3,4-dihydro-1-phenyl-2-(1H)-isoquinolinecarboxylic acid (3S)-1-azabicyclo[2.2.2]oct-3-yl ester 
• 740780-79-4 (3R)-1-azabicyclo[2.2.2]oct-3-yl (1R)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate 
• 22990-19-8 (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline 
• 180468-42-2 (S)-N-carboxylic acid ethyl ester-1-phenyl-1,2,3,4-tetrahydroisoquinoline 
• 1619-34-7 3-quinuclidinol 

Relevant articles and documents

An improved process for the preparation of highly pure solifenacin succinate via resolution through diastereomeric crystallisation

An improved process for the preparation of solifenacin succinate (1) involving resolution through diastereomeric crystallization is described. (1S)-IQL derivative (5) is esterified to form (1S)-ethoxycarbonyl IQL derivative (6) which is condensed with (RS)-3-quinuclidinol (7) to form a solifenacin diastereomeric mixture (8); this is subjected to resolution through diastereomeric crystallization to produce solifenacin succinate (1), which is used for the treatment of an overactive bladder.

A METHOD FOR THE PREPARATION OF SOLIFENACIN

A method of preparing (lS)-(3R)-l-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)- isoquinoline carboxylate (solifenacin) or its pharmaceutically acceptable salts with high optic purity, wherein the crude solifenacin base is transformed to the hydrogen tartrate, which is then optionally transformed to another pharmaceutically acceptable salt or the base of solifenacin. A crystalline salt of solifenacin hydrogen tartrate.